Keywords: بقاء بدون عود; Bladder carcinoma; Cystectomy; Sexual function preserving; Prostate sparing; Neobladder; BC; bladder cancer; BCG; bacillus Calmette-Guérin; CSM; Cancer specific mortality; CSS; Cancer specific survival; CIS; carcinoma in situ; CIC; clean intermittent cat
مقالات ISI بقاء بدون عود (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: بقاء بدون عود; CEA; carcinoembryonic antigen; CT; computed tomography; CTR; consolidation tumor ratio; GGO; ground glass opacity; h-LND; hilar lymph node dissection; LND; lymph node dissection; m-LND; mediastinal lymph node dissection; NSCLC; non-small cell lung cancer;
Keywords: بقاء بدون عود; urinary bladder neoplasms; neoplasm invasiveness; neoplasm recurrence; local; BCG vaccine; mortality; BCG; bacillus Calmette-Guérin; CIS; carcinoma in situ; CR; complete response; DSS; disease specific survival; MIBC; muscle invasive bladder cancer; NMIB
Keywords: بقاء بدون عود; lung cancer; surgical pathology; tumor spread through air spaces; HR; hazard ratio; NSCLC; non-small cell lung cancer; OS; overall survival; RFS; recurrence-free survival; STAKS; spread through a knife surface; STAS; spread through air spaces;
Keywords: بقاء بدون عود; urinary bladder; urinary diversion; robotic surgical procedures; cystectomy; outcome and process assessment (health care); ASA®; American Society of Anesthesiologists®; BMI; body mass index; DSS; disease specific survival; ECUD; extracorporeal urinary d
Keywords: بقاء بدون عود; Krüppel-like factor 4; Meta-analysis; Prognosis; Cancer; Tumor; Carcinoma; TNBC; triple-negative breast cancer; BC; breast cancer; CRC; colorectal cancer; ESCC; esophageal squamous cell carcinoma; GC; gastric cancer; HCC; hepatocellular carcinoma; NPC; n
Keywords: بقاء بدون عود; CLM; colorectal liver metastasis; CSI; cross-sectional image; LTPFS; local tumor progression-free survival; OS; overall survival; RFS; recurrence-free survival;
Keywords: بقاء بدون عود; Female; Multimodal therapy; Overall survival; Recurrence-free survival; Urethral carcinoma;
Keywords: بقاء بدون عود; AR; Amphiregulin; ChIP; Chromatin immunoprecipitation; CM; Conditional medium; EMT; Epithelial-mesenchymal transition; Endostatin; Collagen XVIII; HCC; Hepatocellular carcinoma; HUVEC; Human umbilical vein endothelial cell; IGFBP-3; Insulin-like growth fa
Keywords: بقاء بدون عود; CT; computed tomography; C/T; consolidation/tumor ratio; EGFR; epidermal growth factor receptor; NSCLC; non-small cell lung cancer; OS; overall survival; pD-L1; programmed cell death-1 ligand; PET; positron emission tomography; RFS; recurrence-free surviv
Keywords: بقاء بدون عود; 5FU; 5-fluorouracil; 95%CI; 95% confidence interval; AA; amino acid; AFP; alpha fetoprotein; AML; actue myeloid leukemia; Ang2; angiopoietin 2; ATP; adenosine triphosphate; BCLC; Barcelona-Clinic Liver Cancer classification; BSC; best supportive care; CAP
Keywords: بقاء بدون عود; adjuvants; immunologic; carcinoma; renal cell; kidney neoplasms; ASSURE; Sunitinib Malate or Sorafenib Tosylate in Treating Patients with Kidney Cancer that was Removed by Surgery; CAIX; carbonic anhydrase IX; DFS; disease-free survival; ECOG; Eastern Coo
Keywords: بقاء بدون عود; DSS; disease-specific survival; ESCC; esophageal squamous cell carcinomas; ESD; endoscopic submucosal dissection; HR; hazard ratio; LNM; lymph node metastasis; LVI; lymphovascular invasion; M1; invasion limited to the intraepithelium; M2; invasion limited
Keywords: بقاء بدون عود; DFS; disease-free survival; EGFR; epidermal growth factor receptor; Ex19; exon 19 deletion; Ex21; exon 21 L858R; OS; overall survival; RFS; recurrence-free survival; TKI; tyrosine kinase inhibitor; WT; wild-type;
Keywords: بقاء بدون عود; Non-small cell lung cancer; Geriatric Nutritional Risk Index; Predictive and prognostic factor; AUC; area under the curve; BVI; blood vessel invasion; CEA; carcinoembryonic antigen; CS; cancer-specific survival; CT; computed tomography; CYFRA; cytokeratin
Keywords: بقاء بدون عود; Gamma Knife radiosurgery; Microsurgery; Outcomes and complications; Predictors; GKRS; Gamma Knife radiosurgery; KPS; Karnofsky performance scale; PFS; Progression-free survival; RFS; Recurrence-free survival;
Keywords: بقاء بدون عود; Pancreatic cancer; Neural invasion; Survival; Overall survival; Recurrence-free survival; Disease-free-survival; Systematic review; Meta-analysis;
Keywords: بقاء بدون عود; penile neoplasms; amputation; lymph node excision; referral and consultation; time factors; DSS; disease specific survival; ILND; inguinal lymph node dissection; RFS; recurrence-free survival;
Keywords: بقاء بدون عود; urinary bladder neoplasms; cystectomy; stents; nephrostomy; percutaneous; neoplasm recurrence; local; BC; bladder cancer; CIS; carcinoma in situ; CSS; cancer specific survival; CT; computerized tomography; IVP; excretory urography; RC; radical cystectomy;
Keywords: بقاء بدون عود; fibrosis; neoplasms; germ cell and embryonal; lymph node excision; GCT; germ cell tumor; IGCCCG; International Germ Cell Cancer Collaborative Group; NSGCT; nonseminomatous germ cell tumors; PC-RPLND; post-chemotherapy retroperitoneal lymph node dissection
Keywords: بقاء بدون عود; kidney neoplasms; carcinoma; renal cell; neoplasm recurrence; local; risk; nomograms; BMI; body mass index; RCC; renal cell carcinoma; RFS; recurrence-free survival; SSIGN; Stage, Size, Grade and Necrosis; S-TRAC; Sunitinib as Adjuvant Treatment for Patie
Keywords: بقاء بدون عود; ACM; angle co-occurrence matrix; AFP; α-fetoprotein; AUC; area under curve; HCC; hepatocellular carcinoma; LBP; local binary patterns; MVI; microvascular invasion; NPV; negative predictive value; PPV; positive predictive value; RFS; recurrence-free survi
Keywords: بقاء بدون عود; Clear cell meningiomas; Clinical feature; Predictors; Recurrence; CCM; Clear cell meningioma; CI; Confidence interval; EMA; Epithelial membrane antigen; EOR; Extent of resection; GTR; Gross total resection; HR; Hazard ratio; LI; Labeling index; OS; Overal
Keywords: بقاء بدون عود; OCCC; Ovarian clear cell carcinoma; RFS; recurrence-free survival; OS; overall survival; FIGO; Federation of Gynecology and Obstetrics; WHO; World Health Organization; LVSI; Lymphovascular space invasion; EAOC; Endometriosis-associated ovarian carcinoma;
Keywords: بقاء بدون عود; urinary bladder neoplasms; cystectomy; neoplasm recurrence; local; patient selection; morbidity; BCa; bladder cancer; BCG; bacillus Calmette-Guérin; CG; Clavien grade; CIS; carcinoma in situ; DSS; disease specific survival; LVI; lymphovascular invasion;
Keywords: بقاء بدون عود; Upper tract urothelial carcinoma; Inflammatory markers; Recurrence-free survival;
Keywords: بقاء بدون عود; Desmoid tumor; Aggressive fibromatosis; Recurrence-free survival; Immunohistochemistry; Risk factors; Second recurrence
Keywords: بقاء بدون عود; induction therapy; adjuvant therapy; Masaoka; stage III; thymoma; thymic tumors; multimodality treatment; advanced thymoma; TNM; TT; thymic tumor; OS; overall survival; LAT; locally-advanced thymoma; IT; induction therapy; AT; adjuvant therapy; ESTS; Euro
Keywords: بقاء بدون عود; urethral stricture; anastomosis; surgical; complications; erectile dysfunction; recurrence; ED; erectile dysfunction; NTAR; nonTAR; RFS; recurrence-free survival; TAR; transecting anastomotic repair;
Keywords: بقاء بدون عود; Meningiomas; Neuronavigation; Resection; Utility; CT; Computed tomography; GTR; Gross total resection; KPS; Karnofsky Performance Status; MRI; Magnetic resonance imaging; RFS; Recurrence-free survival; STR; Subtotal resection; WHO; World Health Organizati
Keywords: بقاء بدون عود; Geriatric; Meningioma; Outcomes; Predictors; Resection; GSS; Geriatric scoring system; KPS; Karnofsky performance status; RFS; Recurrence-free survival;
Keywords: بقاء بدون عود; AUC; area under the curve; BVI; blood vessel invasion; CEA; carcino embryonic antigen; CT; computed tomography; CYFRA; cytokeratin 19 fragment; FDG-PET; fluorodeoxyglucose-positron emission tomography; LVI; lymphatic vessel invasion; MRI; magnetic resonan
Keywords: بقاء بدون عود; Breast cancer; Young age; Triple-negative subtype; BRCA mutation; ACOSOG; American college of surgeons oncology group; BCSS; breast cancer-specific survival; BCT; breast-conserving therapy; CI; confidence interval; CBC; contralateral breast cancer; CPM; c
Keywords: بقاء بدون عود; urinary bladder neoplasms; biopsy; neoplasm recurrence; local; cystoscopy; cytology; BCG; bacillus Calmette-Guérin; CIS; carcinoma in situ; CT; computerized tomography; PFS; progression-free survival; RFS; recurrence-free survival; TURBT; transurethral r
Keywords: بقاء بدون عود; urinary bladder neoplasms; prostatic neoplasms; mortality; radiotherapy; cystectomy; CSS; cancer specific survival; DPCT; definitive prostate cancer treatment; OS; overall survival; PCa; prostate cancer; PSM; positive soft tissue surgical margins; RC; rad
Keywords: بقاء بدون عود; Fibromatosis; Surgery; Recurrence-free survival; Risk factorsDF, desmoid-type fibromatosis; FAP, familial adenomatous polyposis; RFS, recurrence-free survival; HR, hazard ratio; 95% CI, 95% confidence interval; PUMCH, Peking Union Medical College Hospital
Keywords: بقاء بدون عود; CT; computed tomography; GGO; ground-glass opacity; MC; main cancer; SN; sub-nodule; CTR; consolidation/tumor ratio; OS; overall survival; RFS; recurrence-free survival; HR; hazard ratio; CI; confidence interval; AIS; adenocarcinoma in situ; MIA; minimall
Keywords: بقاء بدون عود; Breast cancer subtypes; Lymph node status; Overall survival; Recurrence-free survival
Keywords: بقاء بدون عود; DFS; disease-free survival; DSS; disease-specific survival; EGC; early gastric cancer; ER; endoscopic resection; ESD; endoscopic submucosal dissection; OS; overall survival; RFS; recurrence-free survival; SD; standard deviation;
Keywords: بقاء بدون عود; Leukocytosis; Ovarian cancer; Recurrence-free survival; Overall survival;
Keywords: بقاء بدون عود; Epithelial ovarian cancer; Fertility-sparing surgery (FSS); Prognostic factor; Capsule rupture; Recurrence-free survival;
Keywords: بقاء بدون عود; urinary tract; urothelium; carcinoma; fibrinogen; mortality; CSS; cancer specific survival; OS; overall survival; RFS; recurrence-free survival; RNU; radical nephroureterectomy; TN; tumor necrosis; UTUC; upper tract urothelial carcinoma;
Keywords: بقاء بدون عود; CI; confidence interval; CT; computed tomography; F; female; FDG; [18F]-fluoro-2-deoxy-d-glucose; HR; hazard ratio; HRCT; high-resolution computed tomography; IRB; Institutional Review Board; LI; lymphatic invasion; LN; lymph node; LNM; lymph node metasta
Keywords: بقاء بدون عود; Lung adenocarcinoma; Peripheral monocyte counts; Overall survival; Recurrence-free survival; Curative resection; Prognostic factor;
Keywords: بقاء بدون عود; Outcome; Platelet; Radical nephroureterectomy; Recurrence-free survival; Thrombocytosis; Upper tract urothelial carcinoma;
Keywords: بقاء بدون عود; 10; AIS; adenocarcinoma in situ; AUC; area under the curve; CT; computed tomography; LY; lymphatic invasion; MIA; minimally invasive adenocarcinoma; NSCLC; non-small cell lung cancer; PL; pleural invasion; RFS; recurrence-free survival; ROC; receiver op
Keywords: بقاء بدون عود; Adjuvant therapy; Recurrence-free survival; Bone metastases; Bisphosphonates; Health outcomes;
Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma
Keywords: بقاء بدون عود; Cisplatin; Cetuximab; Oropharyngeal neoplasms; Chemoradiotherapy; Head and neck cancer; Human papillomavirus; P16 protein; Oropharyngeal cancer; Dose fractionation; Radiotherapy; CRT; chemoradiation; DMFS; distant-metastasis-free survival; IR-RPA; interme
Radiogenomics and IR
Keywords: بقاء بدون عود; ALK; anaplastic lymphoma kinase; BAP1; BRCA1-associated protein 1; EGFR; epidermal growth factor receptor; HCC; hepatocellular carcinoma; HIF1a; hypoxia-inducible factor-1-alpha; KDM5C; lysine-specific demethylase 5C; KRAS; Kirsten rat sarcoma viral oncog
High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer
Keywords: بقاء بدون عود; CR-1; cripto-1; RFS; recurrence-free survival; DSOS; disease-specific overall survival; OS; overall survival; CEA; carcinoembryonic antigen; Cripto-1; miR-205; NSCLC; Prognostic marker;